Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ospan Mynbaev

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|May 14, 2014
Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized studyChrysoula Kitsou, Ioannis Kosmas, Leandros Lazaros, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|July 15, 2015
Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled studyIoannis P Kosmas, Chrysoula Kitsou, Leandros Lazaros, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|May 14, 2014
Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized studyChrysoula Kitsou, Ioannis Kosmas, Leandros Lazaros, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|July 15, 2015
Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled studyIoannis P Kosmas, Chrysoula Kitsou, Leandros Lazaros, et al.
Pageof 2